Key Highlights

  • Insmed shares are trading 16.30% higher at $112.79 on Thursday, October 29, 2026, with the prior close implied near $96.98 (calculated).
  • Third-quarter total revenue was $524.4 million, up 268% from $142.3 million a year ago.
  • Brinsupri revenue came to $400.1 million, 29% above the second quarter.
  • 2026 Brinsupri guidance rose to $1.35 billion to $1.40 billion from $1.25 billion to $1.40 billion.
  • The net loss shrank to $100.3 million, or $0.46 per share, from $370.0 million, or $1.75 per share.

Insmed Quarterly Report: Why Are Shares Climbing After Brinsupri Passed $400 Million?

Insmed (NASDAQ:INSM) shares are trading 16.30% higher at $112.79 on Thursday, October 29, 2026, after the company posted third-quarter results and increased its 2026 revenue outlook. Total revenue was $524.4 million, up 268% from $142.3 million, and nine-month revenue reached $1,255.9 million against $342.6 million.

Insmed is a biopharmaceutical company with two marketed products: Brinsupri, approved for non-cystic fibrosis bronchiectasis, and Arikayce, a treatment for a chronic lung infection. It is also developing an inhaled treprostinil candidate and several earlier programs. The results call took place at 8:00 a.m. ET on Thursday.

Insmed Product Revenue: How Do Brinsupri and Arikayce Compare?

Brinsupri revenue was $400.1 million, with $398.1 million from the United States, versus $28.1 million a year earlier. Sales grew 29% from the second quarter, and nine-month Brinsupri revenue totaled $917.1 million.

Arikayce revenue was $124.4 million, up 9% from $114.3 million. U.S. sales were $75.5 million, up 2%, and international sales increased 21% to $48.9 million.

Brinsupri won approval in Japan in August 2026 and launched there in October 2026. Total U.S. revenue was $473.6 million, up 364%, while international revenue was $50.8 million, up 26%.

Insmed Losses and Liquidity: What Shifted on the Balance Sheet?

The operating loss narrowed to $89.4 million from $366.0 million. R&D spending rose to $270.0 million from $186.4 million, and selling, general and administrative expense was $253.0 million against $186.4 million. The net loss was $100.3 million, or $0.46 per share, versus $370.0 million, or $1.75 per share.

Cash, equivalents and marketable securities were about $1,146.6 million on September 30, 2026, down from $1,430.0 million at December 31, 2025. Long-term debt was $544.9 million, and accounts receivable climbed to $259.3 million from $140.9 million.

There are 219.3 million shares outstanding, which at today's price implies a market value near $24.7 billion (calculated).

Higher Guidance and Pipeline Progress: What Did Management Increase?

Brinsupri guidance for 2026 is now $1.35 billion to $1.40 billion, up from $1.25 billion to $1.40 billion. Arikayce guidance moved to $460 million to $470 million from $450 million to $470 million. Peak revenue expectations did not change: more than $7 billion for Brinsupri, more than $6 billion for the inhaled treprostinil candidate and more than $1 billion for Arikayce.

In the treprostinil program, over 35% of patients have enrolled in the Phase 3 for pulmonary hypertension with interstitial lung disease, with enrollment due to wrap up in the first half of 2028. A Phase 3 in pulmonary arterial hypertension began enrolling in July 2026, and one in progressive pulmonary fibrosis began in September 2026. Two new directors joined the board in October 2026.

What to Watch Next: The Arikayce Decision Date and the Start of the Fibrosis Trial

The FDA set a Priority Review target date of January 28, 2027 for the Arikayce supplemental application, and Arikayce data are slated to go to Japanese regulators in the fourth quarter of 2026. A Phase 3 in idiopathic pulmonary fibrosis is due to begin in the first half of 2027. The next quarterly update should show whether Brinsupri growth keeps pace with the higher range.